Actinium Pharmaceuticals, Inc. (ATNM) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zevra Therapeutics, Inc.

Applied Therapeutics, Inc.

Zomedica Corp.

Alimera Sciences, Inc.

XOMA Corp.

Fusion Pharmaceuticals, Inc.

Emergent BioSolutions, Inc.

Atara Biotherapeutics, Inc.

Sagimet Biosciences, Inc.

Tenaya Therapeutics, Inc.

Actinium Pharmaceuticals, Inc.

Why is Actinium Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.74%

EBIT Growth (5y)

-28.53%

EBIT to Interest (avg)

-37.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.52

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

29.59%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.33

EV to EBIT

0.55

EV to EBITDA

0.57

EV to Capital Employed

0.53

EV to Sales

-20.65

PEG Ratio

Dividend Yield

ROCE (Latest)

95.75%

ROE (Latest)

-251.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

NET SALES(9M)

At USD 0.09 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Highest at USD -22.87 MM

NET PROFIT(HY)

Higher at USD -11.46 MM

DEBT-EQUITY RATIO (HY)

Lowest at -1,762.72 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-3What is not working for the Company

ROCE(HY)

Lowest at -167.66%

CASH AND EQV(HY)

Lowest at USD 90.13 MM

Here's what is working for Actinium Pharmaceuticals, Inc.

Net Sales

At USD 0.09 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD -22.87 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -11.46 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Profit

At USD -11.46 MM has Grown at 49.26%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -1,762.72 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Actinium Pharmaceuticals, Inc.

Cash and Eqv

Lowest at USD 90.13 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents